Actin / cell migration and repair biology · Peptide
Evidence gap: Route-specific human PK and absolute bioavailability are not established in the imported material.
Open in the interactive library →Compare with other compounds →
The guide cites short-term tolerability of full-length thymosin beta-4, not a retail TB-500 fragment.
Context: Healthy volunteers; phase I; full-length molecule.
Limitations: These doses must not be transferred to TB-500 fragments or KLOW.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment
Human study regimen: Amount: 42 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment
Limitations: Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment
Human study regimen: Amount: 140 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment
Limitations: Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment
Human study regimen: Amount: 420 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment
Limitations: Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Human · Healthy volunteers · Full-length thymosin beta-4; NOT a TB-500 fragment
Human study regimen: Amount: 1260 mg; Frequency: Initially once, then daily; Duration: 14 days in repeated-dose phase; Route: IV; Species: Human; Population: Healthy volunteers; Formulation: Full-length thymosin beta-4; NOT a TB-500 fragment
Limitations: Molecule and IV formulation differ from retail TB-500 / LKKTETQ. Never treat these arms as fragment or KLOW schedules.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Route: Not documented; Sequence: Loading followed by maintenance, as mentioned in the saved synthesis
Limitations: No dose, route, interval or duration is preserved. This is an incomplete anecdotal concept, not a defined regimen.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Amount: 5 mg; Frequency: Twice weekly; Route: Not documented
Limitations: Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.
FDA identifies TB-500 as LKKTETQ; naming is inconsistent in commerce.
Context: Human fragment exposure and musculoskeletal self-treatment remain unresolved in the guide.
Limitations: Verify sequence before borrowing full-length thymosin beta-4 evidence.
These compounds share an Atlas pathway label. That is a navigation connection, not evidence of equivalent effects or suitability together.
Browse this pathway in the library →Educational research summary. Study amounts are research context, not a dose recommendation. Not medical advice.